Parents Appear Receptive to Children Receiving HPV Vaccine at 9 or 10 Years of Age
MONDAY, June 2, 2025 -- Clinicians consider administration of human papillomavirus (HPV) vaccine as feasible at age 9 to 10 years, and parents appear to be receptive to discussing vaccination at this age, according to a study published online June 2 in Pediatrics.
Caroline K. Tietbohl, Ph.D., from the University of Colorado and Children's Hospital Colorado in Aurora, and colleagues conducted an explanatory sequential mixed-methods study as part of an ongoing randomized trial that compared initiation at ages 9 to 10 years (intervention) versus 11 to 12 years (control) across 17 practices in Colorado (nine intervention) and 16 practices in California (eight intervention). At one month after study initiation, practice clinicians were surveyed, and semistructured interviews were conducted at three months after study initiation.
One-month surveys were completed by 66 and 39 Colorado and California clinicians (92 and 87 percent, respectively); 90 and 77 percent, respectively, were routinely initiating vaccines at age 9 or 10 years. The researchers found that most clinicians reported that vaccination at ages 9 to 10 years was not burdensome; issues were mainly unchanged, including parental concerns and discussion times. According to interviewees, many parents seemed receptive to discussing HPV vaccination at ages 9 to 10 years; pushback often resulted from child expectations for a vaccine-free visit at age 9 years, rather than concerns relating to vaccination. Since sexual activity was not perceived as salient, discussions at ages 9 to 10 years were shorter. The option of spacing out vaccines was preferred by many, with administration of a single vaccine at age 9 years and fewer at age 11 years.
"The results of our prospective trial will determine if initiating vaccination earlier increases vaccination completion rates, especially by age 13 years," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Circulating Tumor HPV DNA Can ID HPV+OPSCC Years Before Diagnosis
MONDAY, Sept. 22, 2025 -- Circulating tumor human papillomavirus DNA (ctHPVDNA) can be detected in the blood years prior to HPV-associated oropharyngeal squamous cell carcinoma...
Nonadherence to Cervical Cancer Screening Increased After COVID-19 Pandemic
THURSDAY, Sept. 18, 2025 -- Nonadherence to cervical cancer screening in the United States increased after the COVID-19 pandemic, according to a study published online Sept. 10...
Influenza-Linked Hospitalization Rate High in 2024 to 2025 Flu Season
WEDNESDAY, Sept. 17, 2025 -- The cumulative influenza-associated hospitalization rate for the 2024 to 2025 season surpassed all end-of-season rates during the period beginning...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.